CTOs on the Move

Murad

www.murad.com

 
People come to Murad when they`re ready to transform the life of their skin. Murad guarantees that transformation because only Murad combines advanced scientific research and practical clinical experience to create high performance skincare products, dietary supplements and lifestyle programs that help people look and feel their absolute best. As America`s first authentic doctor-developed brand, Murad remains true to the scientific principles of its founder, world-renowned dermatologist Howard Murad, M.D. Shaped by his Inclusive Health philosophy and inspired by the real problems of the more than 50,000 patients and clients who have visited his Los Angeles dermatology practice and Inclusive Health ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.murad.com
  • 2141 Rosecrans Ave #6100
    El Segundo, CA USA 90245
  • Phone: 310.335.1700

Executives

Name Title Contact Details

Similar Companies

Kootenai Medical Center

Kootenai Health provides a comprehensive range of medical services to patients in north Idaho, eastern Washington, Montana and the Inland Northwest at several facility locations. The main campus at Kootenai Health is located in Coeur d`Alene, Idaho and includes a 299-bed community-owned hospital. By providing outstanding health care, Kootenai Health repeatedly earns regional and national recognition.

CellOxess

CellOxess is a Pennington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Omega Healthcare Management Services

Omega is the premier offshore provider of healthcare outsourcing services. We specialize in medical billing, coding, accounts receivable management, and other healthcare-related services.

Nexgel

NEXGEL Advanced Hydrogel Solutions in a manufacturer of unique trans-dermal delivery system that was originally developed and FDA-approved for the Hospital Wound Care market, and is now being deployed against Consumer OTC, Rx, Medical Device and Cosmetic applications.

Acucela

Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.